Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2019-09-30 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received approval from the Russian Ministry of Healthcare to market a new pharmaceutical product. It is addressed to stock exchanges and includes a media release. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The content is a corporate announcement about product approval and market entry, which fits the category of a general regulatory announcement or compliance communication. The document length is under 5,000 characters and it is primarily an announcement rather than a detailed report or filing. Therefore, it best fits the Regulatory Filings (RNS) category as a general regulatory announcement.
2019-09-30 English
Shareholders meeting
Regulatory Filings
2019-09-27 English
Press Release
Environmental & Social Information Classification · 95% confidence The document is a press release dated September 26, 2019, from Glenmark Pharmaceuticals announcing its inclusion in the Dow Jones Sustainability Emerging Markets Index for the second consecutive year. It highlights the company's sustainability achievements and rankings. The content focuses on environmental, social, and governance (ESG) performance and sustainability benchmarks. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is a public announcement about sustainability recognition, which aligns with Environmental & Social Information filings. It is not a report publication announcement or a regulatory filing, as it contains substantive information about ESG performance and company recognition in sustainability indices.
2019-09-26 English
Press Release
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received Orphan Drug Designation from the FDA for a drug candidate GBR 1342. It is addressed to stock exchanges and includes a media release. There are no financial statements, no detailed financial performance data, no management discussion of financial results, no regulatory certifications, or voting results. The content is a corporate announcement about a regulatory milestone related to drug development. It is not an annual report, earnings release, management report, or any other financial filing. The document is a public announcement of a corporate event, best classified as a Regulatory Filing (RNS) since it does not fit other specific categories and is a general regulatory announcement to the stock exchanges.
2019-09-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific pharmaceutical product. It is a media release intended for public and regulatory record, not a financial report or detailed filing. The document is relatively short (3843 characters) and serves as an announcement rather than a detailed report or financial statement. There is no indication of financial data, management discussion, or regulatory certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-09-10 English
Shareholders meeting
Regulatory Filings
2019-09-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.